Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 7, 2016, Pages 1393-1403

  van Vlijmen, E F W ^a   Wiewel Verschueren, S ^a   Monster, T B M ^a   Meijer, K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

combined oral contraceptives; hereditary; meta analysis; thrombophilia; venous thromboembolism

Indexed keywords

ADENINE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; GUANINE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTITHROMBIN DEFICIENCY; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE SEVERITY; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84990242141     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13349     Document Type: Article

References (44)

1. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
2. van Hylckama V, Helmerhost FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
3. deBastos M, Stegeman BH, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database of Systematic Reviews 2014; Issue 3. Art. No.: CD010813 doi:10.1002/14651858.CD010813.pub2.
4. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
5. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593–6.
6. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol 1997; 34: 171–87.
7. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4.
8. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siskovick DS, Hillarp H, Watzke HH, Bernardi F, Cumming AM, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706–8.
9. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106–12.
10. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87–93.
11. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636.
12. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809–16.
13. Ehrenforth S, Nemes L, Mannhalter C, Rosendaal FR, Koder S, Zoghlami-Rintelen C, Pabinger I. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:1691A. J Thromb Haemost 2004; 2: 430–6.
14. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, Coccheri S. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002; 23: 984–90.
15. World Health Organisation. Medical Eligibility Criteria for Contraceptive use. Reproductive Health and Research, 5th ed. Geneva, Switzerlanda: World Health Organization, 2015.
16. Wells G, Shea B, OConnell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 17 June 2016.
17. deBruijn SFTM, Stam J, Koopman MMW, Vandenbroucke JP for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998; 316: 589–92.
18. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sorensen HT, Baech J, Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 28–31.
19. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998; 244: 27–32.
20. Martinelli I, Sacchi E, landi G, Taioli E, Duca F, Manucci PM. High risk of cerebral vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793–7.
21. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Manucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptives use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700–3.
22. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000; 5: 105–12.
23. Aznar J, Vaya A, Estelles A, Mira Y, Segui R, Villa P, Ferrando F, Falco C, Corella D, Espana F. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000; 85: 1271–6.
24. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49–52.
25. Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452–7.
26. Martinelli I, Battaglioli T, Buccarelli P, Passamonti SM, Manucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110: 566–70.
27. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004; 70: 3–10.
28. Gadelha T, André C, Jucá AAV, Nucci M. Prothrombin 20210ª and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis 2005; 19: 49–52.
29. Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11: 124–31.
30. Tufano A, Guida A, Coppola A, Nardo A, Capua MD, Quintavalle G, Di Minno MND, Cerbone AM, Di Minno G. Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfus 2014; 12: s337–42.
31. Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, Björgell O, Kieler H. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124: 600–9.
32. Pabinger I, Schneider B, and the study GTH group on natural inhibitors. Thrombotic risk of women with hereditary antithrombin III, protein C- and protein S deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548–52.
33. Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyák K, van der Meer J, Büller HR. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15–20.
34. van Boven HH, Vandenbroucke JP, Briët E, Rosendaal FR. Gene-gene and gene-environment interactions determine the risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999; 94: 2590–4.
35. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198–202.
36. Santamaria A, Mateo J, Oliver A, Menendez B, Souto J, Borrel M, Fontcuberta J. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the thrombin gene. Haematologica 2001; 86: 965–71.
37. van Vlijmen EFW, Brouwer JL, Veeger N, Eskes TK, Graeff PA, van der Meer J. Oral Contraceptives and the Absolute Risk of Venous Thromboembolism in Women With Single or Multiple Thrombophilic Defects. Arch Intern Med 2007; 167: 282–9.
38. van Vlijmen EF, Veeger N, Middeldorp S, Hamulyák K, Prins MH, Büller HR, Meijer K. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118: 2055–61.
39. Bezemer ID, van der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610–5.
40. Noboa S, Le Gal, Lacut K, Mercier B, Leroyer C, Nowak E, Mattier D, Oger E for the EDITH Collaborative Study Group. Family history as a risk factor for venous thromboembolism. Thromb Res 2008; 122: 624–9.
41. Dowling NF, Austin H, Diley A, Whitsett C, Evatt BL, Hooper WC. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. J Thromb Haemost 2003; 1: 80–7.
42. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998; 158: 585–93.
43. Middeldorp S. Is thrombophilia testing useful? Hematology Am Soc Hematol Educ Program. 2011; 2011: 150–5.
44. Lidegaard Ø. Hormonal contraception, thrombosis and age. Expert Opin Drug Saf 2014; 13: 1353–60.